Assessment of long-term anticoagulation in patients with a continuous-flow left-ventricular assist device: A pilot study  by Jennings, Douglas et al.
BRIEF CLINICAL REPORTSAssessment of long-term anticoagulation in patients with
a continuous-flow left-ventricular assist device: A pilot studyDouglas Jennings, PharmD, BCPS, Jane McDonnell, PharmD, and Jessica Schillig, PharmD, BCPS,
Detroit, MichThe HeartMate II, developed by the Thoratec Corporation
(Thoratec Corporation, Pleasanton, Calif), is a continuous
axial-flow left ventricular assist device that has shown
promising results for extended mechanical circulatory sup-
port. Patients with this device usually receive long-term an-
ticoagulation to prevent thrombosis and ischemic stroke;
however, patients with this device also seem to have an
elevated risk of bleeding.1 Anticoagulation must therefore
be optimized in these patients to protect against thrombo-
embolism but also minimize bleeding risks.
Currently, data describing the long-term outpatient anti-
coagulation in patients with the HeartMate II are limited.
The purpose of our pilot study was to characterize the
long-term outpatient anticoagulation regimen for Heart-
Mate II recipients with regard to time within the therapeutic
international normalized ratio (INR) range, weekly warfa-
rin dose, and incidences of bleeding and thromboembolic
events.MATERIALS AND METHODS
This study included patients with the HeartMate II implanted from
June 1, 2008, to May 31, 2009, at Henry Ford Hospital, an 806-bed ter-
tiary care teaching facility. Data collection included patient demo-
graphic data, medical history, laboratory values, and interacting
medications. The primary end point measured was time within therapeu-
tic INR range, defined as an INR of 2 to 3 during the period of data col-
lection. The historical average time in the therapeutic range for the
overall clinic population was the comparator group. Secondary end
points included time above and below the therapeutic INR range, me-
dian weekly warfarin doses, and incidences of thromboembolic and
bleeding events. Bleeding was defined according to the Thrombolysis
in Myocardial Infarction study criteria, and thrombosis was defined as
any newly diagnosed stroke, venous thromboembolism, or device throm-
bosis. Data were gathered from computerized progress notes from the
institution’s outpatient pharmacist-managed anticoagulation clinics.
The number of patient days within, above, and below the therapeutic
INR range was calculated according to Rosendaal and colleagues’
method for linear interpolation.2From the Department of Pharmacy Services Henry Ford Hospital, Detroit, Mich.
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A total of 16 patients (average age, 53 years; 62%
African American; 81% male; 31% bridge to transplant)
yielded 576 INR values and 5004 days of follow-up.
The average time in the therapeutic range for HeartMate
II recipients was 51% (range, 22%–88%), which is sig-
nificantly worse than the 68% time within range for our
overall clinic population. Average times above and below
the therapeutic range for the HeartMate II group were
17% and 32%, respectively. Every patient had at least
one nontherapeutic INR value, and the median time within
range was 49%. The median weekly warfarin dose for
these patients was 35 mg (range, 16–70 mg). There were
no outpatient bleeding episodes. One patient had a tran-
sient ischemic attack as an outpatient (INR 1.6 at the
time).DISCUSSION
Our study suggests that HeartMate II patients may spend
less time in their target INR range than the overall popula-
tion at our anticoagulation clinic. The reasons for this devi-
ation are unclear. Previous studies have demonstrated the
potential of theHeartMate II to alter the coagulation cascade
by inducing a deficiency of von Willebrand factor.1 It is
possible that this device could produce other physiologic
changes in the coagulation system that might influence the
pharmacodynamic response to warfarin. Additionally, phar-
macogenomic mutations may also have influenced warfarin
response in these patients.
Previous reports describinganticoagulation inpatientswith
the HeartMate II are limited. John and coworkers3 followed
up 45 HeartMate II recipients for 7 months and reported an
overallmedian INR range of 1.6 to 2.0,whereasBoyle and as-
sociates4 followed up 331 patients with the device as a bridge
to transplant for 6months and reported amedian INR value of
2.1. Neither of these studies calculated a time within range
with linear interpolation. Furthermore, both studies only re-
corded INR values once a month or when a clinically signif-
icant event occurred (eg, bleeding). In contrast, our study
followed up patients for as long as 1 year and measured
INR values at least monthly, or as frequently as weekly if pa-
tients were out of range.We believe that this closemonitoring
increased the ability of our study to detect subtle fluctuations
in the anticoagulation of these patients.
Our study has several limitations that warrant further
discussion. First, it is a single-center, retrospective analy-
sis. Also, baseline characteristics for the comparator groupardiovascular Surgery c Volume 142, Number 1 e1
Brief Clinical Reportsare not available, because the time within range for these
patients was drawn from historical data obtained from
our anticoagulation clinic. Finally, although linear interpo-
lation is a well validated and accurate method for estimat-
ing time within the therapeutic INR range, it is still
possible that not all fluctuations in the INR were detected
by this analysis.
In conclusion, the results of our pilot study suggest that
HeartMate II recipients may spend a significant amount of
time with values outside the target INR range. We saw
this deviation despite relatively normal warfarin dosage
requirements. Additional studies exploring the etiology of
this potentially altered pharmacodynamic response are war-
ranted. Practitioners implanting left ventricular assistFrom the Departments of Thoracic Surgerya and Histopathology,b Guy’s Hospital,
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to ensure optimal levels of anticoagulation.References
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Transplant. 2009;28:881-7.An unusual case of chyloptysisRebecca Tregunna, MBBS, BSc,a Elizabeth Belcher, MRCP, FRCS, PhD,a Paul Cane, FRCPath,b and
Loic Lang-Lazdunski, MD, PhD,a London, EnglandChyloptysis is rare and usually occurs spontaneously sec-
ondary to disorders of the mediastinal lymphatic system.
We present a case of chyloptysis after cervical mediastino-
scopy and biopsy of mediastinal lymphadenopathy.CLINICAL SUMMARY
A 59-year-old man presented with a 3-month history of
a cough producing white sputum streaked with occasional
minor hemoptysis. His medical history was unremarkable
other than a pericardial effusion, not noted to be chylous
in nature and of unknown cause, requiring percutaneous
drainage without complication 10 years previously. He
was a nonsmoker. Examination results were unremarkable
with no evidence of yellow nail syndrome. Computed to-
mography (CT) of the chest demonstrated widespread para-
tracheal lymphadenopathy, anterior mediastinal mass, and
normal lung fields (Figure 1, A). Subsequent bronchoscopy
results were normal. Cervical mediastinoscopy confirmed
extensive mediastinal lymphadenopathy. Chyle was noted
to reflux on manipulation of tissues; however, no evidenceof elevated lymphatic pressure or hemorrhage was noted.
Biopsy of mediastinal nodes (stations 2 and 4) was without
complication and showed only reactive changes, with no
evidence of granuloma formation or malignancy after histo-
pathologic examination.
After this procedure, the patient presented again with
aworsening cough and shortness of breath. He now described
his sputum as being of ‘‘fried egg’’ appearance. Analysis of
sputum confirmed chyloptysis (triglyceride, 14.7 mmol/L;
cholesterol, 2.0 mmol/L [ratio 7.4:1]). Repeat CTof the chest
showed a 90-mm anterior mediastinal mass with patchy pa-
renchymal opacification in the lingula and left lower lobe,
but no evidence of pleural effusion (Figure 1,B). Lymphangi-
ography was not undertaken. The patient underwent median
sternotomy and resection of this anterior mediastinal mass.
At operation, chyle was noted draining from the cut tumor
surface. Multiple small vessels were noted between the
mass and hilum of the left lung, which were divided using
the Harmonic scalpel; however, the mass did not invade
into the lung parenchyma, and pulmonary resection was not
deemed necessary. BioGlue (CryoLife, Europa Ltd, Surrey,
UK) was applied over the resection area in an attempt to re-
duce the risk of chylothorax in the early postoperative period.
Histopathologic examination showed predominantly
adipose tissue interspersed with cystically dilated spaces
containing grey, chylous fluid and multiple congested blood
vessels with focal punctate hemorrhage confirming a typical
lymphangioma (Figure 2). The patient made a satisfactory
postoperative recovery with no further chyloptysis at
7 months postoperatively.ry c July 2011
